Nektar Therapeutics
Nektar and SFJ collaborate to develop experimental head and neck cancer drug
February 18, 2021Cancer, Nektar Therapeutics
Nektar Therapeutics has announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of Bempegaldesleukin (BEMPEG), an investigational CD122-preferential …
Takeda ordered to pay Bayer $155.19 million over patent infringement
February 6, 2019Research and Development Baxalta, Bayer, Nektar Therapeutics, Takeda, adynovate
A US court has ordered Takeda Pharmaceutical’s Baxalta unit to pay German firm Bayer AG $155.19 million for infringement of …
Top Ten most popular articles on Pharmafile.com this week
February 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Allergan, Antibiotics, Avycaz, Elastagen, FDA, GSK, India, J&J, JJ, Nektar Therapeutics, Novartis, Theravance, artificial intelligence, pharma
It’s top ten time again. This week, among our most popular stories was the worrying news that, accoridng to research …
Rapidly-growing Nektar Therapeutics reportedly considering sale of its business
February 5, 2018Manufacturing and Production, Sales and Marketing M&A, MA, Nektar, Nektar Therapeutics, acquisition, pharma
After a slew of M&A deals throughout the first month of 2018, including Celgene’s buyout of Juno Therapeutics for $9 …
Bayer’s $175 million pneumonia drug fails at phase 3
November 27, 2017Research and Development, Sales and Marketing Amikacin, Amikacin Inhale, Bayer, Nektar Therapeutics, pharma
Bayer has been hit by the news that its latest effort in the pneumonia space failed at the Phase 3 …
